Microbiologics is investing in an additional 650-sq.-ft. Biosafety Level 3 (BSL-3) facility within its existing building at its global headquarters in St. Cloud, MN. This addition follows the recent completion of its first BSL-3 lab at the company’s San Diego, CA facility in August 2020. The additional BSL-3 facility allows for increased capabilities and capacity to provide anti-infective testing, assay development and biomaterial production services for highly infectious pathogens, including COVID-19 and other emerging diseases.
 
Brad Goskowicz, Microbiologics Chief Executive Officer, said, “Demanding timelines and complex regulatory requirements are prompting pharmaceutical and diagnostic companies to outsource aspects of their R&D and QC functions to a qualified CRMO partner. We’re able to provide end-to-end, highly-collaborative support where and when our clients need it, which enables them bring new products to market rapidly and safety.”
 
Microbiologics is a contract research and manufacturing organization providing antiviral testing and assay development services to support drug, vaccine and medical device development processes from discovery through post-market surveillance. Examples of these specialized assay services include virus neutralization, hemagglutination, immunoassay development within ELISA platforms and Single Radial Immunodiffusion (SRID) assays. Microbiologics is currently transferring a SARS-CoV-2 virus neutralization assay for the U.S. Biomedical Advanced Research and Development Authority (BARDA).